Fecal SN-38 Content as a Surrogate Predictor of Intestinal SN-38 Exposure and Associated Irinotecan-induced Severe Delayed-Onset Diarrhea by a Novel Use of the …

Z Zheng, VT Šaponjac, R Singh, J Chen… - Pharmaceutical …, 2024 - Springer
Background Irinotecan administration can lead to severe delayed-onset diarrhea (SDOD) in
clinical practice. Currently, there is no reliable surrogate predictor of intestinal exposure to …

Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats

XY Chu, Y Kato, Y Sugiyama - Cancer Research, 1997 - AACR
We have reported previously that a canalicular multispecific organic anion transporter
(cMOAT) is responsible for the biliary excretion of carboxylate forms of irinotecan, 7-ethyl-10 …

Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1

FR Luo, PV Paranjpe, A Guo, E Rubin… - Drug metabolism and …, 2002 - ASPET
Irinotecan (CPT-11) is a water-soluble camptothecin (CPT) derivative that has been recently
approved in the United States for patients as a first-line therapy in advanced colorectal …

[引用][C] Effect of S‐1 on pharmacokinetics of irinotecan in a patient with colorectal cancer

K Yokoo, H Watanabe, A Hamada… - Clinical …, 2006 - Wiley Online Library
Pharmacokinetic modulation of irinotecan (CPT-11) with cyclosporine (INN, ciclosporin) and
phenobarbital has been reported in the Journal. 1 CPT-11 is widely used in the treatment of …

A novel irinotecan derivative ZBH-1207 with different anti-tumor mechanism from CPT-11 against colon cancer cells

D Zhao, D Wu, G Zhang, Y Li, W Shi, B Zhong… - Molecular Biology …, 2022 - Springer
Abstract Purpose Irinotecan (CPT-11) is a camptothecin derivative whose potent anti-tumor
activity depends on the rapid formation of an in vivo active metabolite, SN38 (7-ethyl-10 …

Metabolic activation of irinotecan during intra-arterial chemotherapy of metastatic colorectal cancer

M Czejka, A Kiss, C Koessner, R Terkola… - Anticancer …, 2011 - ar.iiarjournals.org
Biotransformation of irinotecan (CPT-11) into its pharmacologic active metabolite SN-38 was
investigated in patients treated for advanced colorectal cancer. A dose of 180 mg/m2 CPT …

Intraperitoneal administration of CPT-11 in rats--experimental study for pharmacokinetics

T Nagahama, M Maruyama, N Goseki - Gan to Kagaku ryoho …, 2000 - europepmc.org
The pharmacokinetics of CPT-11 administered into rats to evaluate the future possibility of ip
administration was investigated. Serum, bile juice, and intraperitoneal fluid was collected to …

In situ intestinal perfusion of irinotecan: application to P-gp mediated drug interaction and introduction of an improved HPLC assay

AK Rabba, L Si, K Xue, M Li… - Journal of Pharmacy & …, 2011 - journals.library.ualberta.ca
PURPOSE: To determine experimentally the intestinal permeability of the anticancer
prodrug irinotecan, and to quantify the amount of its cytotoxic metabolite SN-38 that is …

Novel agents that potentially inhibit irinotecan-induced diarrhea

X Yang, Z Hu, SY Chan, E Chan… - Current medicinal …, 2005 - ingentaconnect.com
Irinotecan (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has
exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA …

Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver

C Farabos, MC Haaz, P Gires, J Robert - Journal of pharmaceutical …, 2001 - Elsevier
Abstract Irinotecan (CPT‐11) is a semisynthetic derivative of camptothecine that has proved
activity in the treatment of colorectal carcinoma. The metabolites identified in humans …